Cipla involves in pharmaceutical sector, headquartered in Mumbai. Cipla is a leader in the pharmaceutical industry. Cipla develops medicine to treat diabetes, depression, respiratory deseases, etc
Latest Updates
Today Cipla stock price is 8% up from the previous day. That means in a single day it has given a return of 8% to their investor. Cipla stock should be must their in your portfolio, in long term it will give a good return.
Today the Cipla stock price is running around 1400rs. Actually the stock price is running at “all time high”. In 52 week range the stock price had make a high of 1425rs and low of 852. It is high volume stock and their daily volume is more than 75 lakh.
Big shark investor
HDFC group holds a 4.32% holding.
ICICI group has a holding of 1.02%
Government pension fund has a holding of 2.92%
About Company
It has a market cap of 113756 Crore which is greater than Divis labs, Dr. Reddy, Mankind, etc. It has a ROE of 12 and debt to equity is 0.02.Promoters holding is at 33.47% in Dec 2023 quarter. FII holding is at 25.73% in Dec 2023 quarter. Mutual funds holding is at 16.66% in Dec 2023 quarter.
Announcement & Dividends
Announcement
Cipla has announced the board meeting on 25 January 2024.
Dividends
Cipla gives good Dividends to their investor every year. Comparing with other stocks the dividends of cipla is very low.
Some more information to be know before Investing
Cipla in Q3 FY24, the first pharma measure to come out with its earnings where we have seen the numbers beating the estimates, especially onto the margin fund, which were higher than the whole year guidance of FY24 given by the company and not just that, across the segments, across the geographies, we have seen double digit growth coming in for Cipla where in this time, the US sales has hit an all -time high levels for the company. Let’s talk numbers then. The revenue has seen a jump of 14 percent, while the EBITDA has seen a jump of 24 percent and the margins have seen an improvement from 24 .2 percent to 26.4 percent and onto the profit figure, there inis a jump of 32 percent but this time, there is an impairment cost of 195 crores and adjusting to that, the profit stands at 1200 crores which actually beats our estimates. India and US both has seen great growth in terms of the performance across the board because India business has seen a jump of 12 percent on the back of growth across branded prescription, trade generics, consumer health and for the US business, highest ever quarter at 230 million dollars above.
Disclaimer: The views and recommendations given in this article are those of individual analysts. We advise investors to check with certified experts before taking any investment decisions.